News &amp; Updates

Treatment with 5-fluorouracil (5-FU) 5% cream tends to end in failure with shorter treatment duration and larger lesion size in patients with squamous cell carcinoma in situ (SCCis), a study has shown.

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

05 Mar 2025

Once-weekly semaglutide shows promise in alcohol use disorder

Low-dose semaglutide may reduce alcohol craving and some drinking-related outcomes in patients with alcohol use disorder (AUD), a randomized clinical trial has shown.

Once-weekly semaglutide shows promise in alcohol use disorder

GLP-1 receptor agonists reduce more fat than muscle mass

Glucagon-like peptide-1 (GLP-1) receptor agonists likely induce weight loss by reducing more fat mass than muscle mass, a research team from the University of Hong Kong (HKU) has found.

GLP-1 receptor agonists reduce more fat than muscle mass

No cardiovascular signal with anti-CGRP mAbs for migraine

Migraine treatment with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor does not appear to contribute to increased risk of cardiovascular disease (CVD) compared with onabotulinumtoxinA in adults, including those who are older and with disability, according to a retrospective cohort study.

No cardiovascular signal with anti-CGRP mAbs for migraine

Evolving role of alectinib in ALK-positive NSCLC

The prognosis of patients with non-small-cell lung cancer (NSCLC) has markedly improved since the identification of oncogenic driver mutations and concomitant discovery of tyrosine-kinase inhibitors (TKIs). At an industry-sponsored meeting during the Immuno-Oncology Hong Kong (IOHK) 2024 conference, Professor Solange Peters of the University of Lausanne in Switzerland shared her insights and experiences in the management of patients with ALK-positive NSCLC and highlighted the importance of considering toxicity profiles when choosing between ALK TKIs.

Evolving role of alectinib in ALK-positive NSCLC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

De-escalating ticagrelor monotherapy reduces bleeding in ACS

De-escalation of dual antiplatelet therapy (DAPT) to ticagrelor monotherapy results in a decreased risk for major bleeding compared with standard DAPT among patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, reports a study.

De-escalating ticagrelor monotherapy reduces bleeding in ACS

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Does SEP-1 increase sepsis mortality?

Implementation of or compliance with the Severe Sepsis and Septic Shock Management Bundle (SEP-1) does not appear to contribute to mortality among patients with sepsis, as shown by the results of a systematic review.

Does SEP-1 increase sepsis mortality?